Lv3
220 积分 2021-08-17 加入
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
16小时前
已完结
Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer
3个月前
已完结
Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis
2年前
已完结
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy
2年前
已完结
Potential of Liposomes for Enhancement of Oral Drug Absorption
2年前
已关闭
44. HS 3014
2年前
已完结
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
2年前
已完结
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
3年前
已完结
Association between HER2 status in residual disease and sensitivity to trastuzumab emtansine
3年前
已完结
Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
3年前
已完结
皖公网安备34019202002308
